CinRx is a biotechnology company founded in 2015 that leverages its team’s exceptional industry experience to develop therapeutics in a novel way that meets the modern paradigm of drug development. CinRx acquires compounds from multiple sources, as well as partners with other biotechnology companies, to invest in and develop innovative products that will transform the lives of patients. With its broad preclinical, clinical pharmacology, medical, biostatistical and regulatory expertise, CinRx accelerates drug development programs to help achieve marketing approval or bring about a successful commercial exit.
JD General Counsel, Medpace, Inc.
Founder and CEO Dr. Jon Isaacsohn has more than 30 years of experience developing hundreds of drugs from protocol design to global submissions (including 30 NDAs) and was the co-founder of Medpace, Inc. He has decades of experience in academia, pharmaceuticals and clinical medicine. Dr. Isaacsohn formerly served as the Chief Medical Officer of Teva, where he was responsible for specialty drug development, including about 160 clinical trials, as well as the company’s New Therapeutic Entity Initiative, the safety of all marketed products and the Global Health Program.
Chief Operating Officer Catherine Pearce, MBA, DHSc has more than 20 years of experience in pharmaceutical clinical development, business development and R&D at companies including Merck, Ethicon and Medpace. Most recently, she served as the Vice President of Research and Development, NTEs at Teva, where she was responsible for developing over 20 repurposed products across multiple therapeutic areas.
Chief Medical Officer Brian Murphy, MD, MPH is board-certified in infectious disease, internal medicine and pediatrics, and has more than 15 years of experience in clinical trial and drug development as an academic investigator and Vice President of Medical Affairs at Medpace. He has worked with large and small biopharmaceutical companies, government agencies, public-private partnership, and academic centers to achieve the approval of multiple products across various therapeutic areas.
Senior Director of Clinical Pharmacology Mary Bond, MS, MBA has more than 20 years of industry experience in early clinical development, leading numerous clinical pharmacology programs for both small and large molecules at SmithKline Beecham, GlaxoSmithKline, Cephalon, and Teva. She has been responsible for the design and oversight of more than 100 early phase studies and has contributed to more than 12 INDs/CTAs and 15 marketing applications both in the U.S. and abroad.
Senior Director of Business Development Justin Thompson, MS, recently spent nearly a decade at CincyTech, a seed stage investment fund, where he focused on new company investment, portfolio company management and internal operations, and participated in more than 60 new company financings. Among the companies he worked with at CincyTech are AssureX Health (purchased by Myriad Genetics), Enable Injections, Akebia Therapeutics (NASDAQ: AKBA), and Blue Ash Therapeutics (purchased by Forest Laboratories).
Steven Johnson, PharmD
Dr. Johnson currently serves as the Vice President of Regulatory Affairs for Medpace, and is globally responsible for all regulatory affairs and medical writing activities. Dr. Johnson completed his Bachelor of Science, Bachelor of Pharmacy, and Doctor of Pharmacy degrees atWashington State University. He has over 18 years of experience in regulatory drug development, of which eight were at the FDA as a Clinical Pharmacology Extern, Clinical Pharmacology Reviewer, and eventually, a Master Reviewer in the Division of Metabolic and Endocrine Drug Projects (Rockville, MD). Dr. Johnson’s regulatory expertise spans across many areas, including global regulatory strategy development, clinical development, licensing applications (NDA, BLA, MAA), investigational applications (IND & CTA), and regulatory planning, review, critique, and plan execution. He has gained extensive knowledge through his work with the following regulatory agencies: US FDA, EMA (CHMP; PDCO); EU National Authorities (e.g. DHMA, PEI, BfRM, MHRA); Health Canada; PMDA.
Mark Kessel, JD
Dr. Kessel co-founded Symphony Capital LLC, a private equity firm investing in the clinical development programs of biopharmaceutical companies. He is widely recognized as a leader in structuring product development investments for the biopharmaceutical industry. Mr. Kessel was formerly the managing partner of Shearman & Sterling, with day-to-day operating responsibility,and is currently of-counsel to the Firm, where he co-heads its healthcare practice. He is also the Chairman of the Foundation for Innovative New Diagnostics (FIND), a member of Fondation Santé, an Editorial Advisor to Nature Biotechnology and a director of Organovo and Vincerx. He previously served on strategic advisory committees of biotechnology companies, as a director of the Global Alliance for TB Drug Development, the Biotechnology Industry Organization, Dynavax Technologies Corporation, OXiGENE, Inc., Antigenics, Inc., Heller Financial Inc., and Harrods (UK) Limited, a Trustee of the Museum of the City of New York and on the advisory committee of the Mt. Sinai Rape Crisis Center. He has written for the biotech industry and on world health for Nature Reviews Drug Discovery, Nature Biotechnology, The Lancet, The Scientist, Science Translational Medicine, Start-Up, BioCentury and other publications, and on issues related to governance for such publications as The Wall Street Journal, Financial Times, The Deal, NACD Directorship, BNA’s Corporate Counsel Weekly, Bloomberg BNA, Corporate Law & Accountability Report, and Euromoney. He received a B.A. with honors in Economics from the City College of New York, and a J.D. magna cum laude from Syracuse University College of Law.